EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects

Tomasz Wasiak iD, Maria Jaskólska, Kamil Filiks iD, Jakub Bartkowiak, Adrianna Rutkowska iD

Cells · 2026

DOI: 10.3390/cells15030309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Tomasz Wasiak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, LEK-AM Pharmaceutical Company Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy (LB) offers a minimally invasive approach to characterizing and monitoring glioblastoma (GB), a tumor marked by extensive heterogeneity, limited surgical accessibility and rapid molecular evolution. By analyzing circulating tumor-derived components such as circulating tumor DNA (ctDNA), extracellular vesicles (EVs), circulating RNA species and circulating tumor cells (CTC), LB provides dynamic molecular information that cannot be captured by neuroimaging or single-site tissue sampling. Cerebrospinal fluid (CSF) currently yields the highest sensitivity for detecting tumor-specific alterations, while plasma enables repeat monitoring despite lower biomarker abundance. EVs have gained particular prominence due to their ability to preserve DNA, RNA, and protein cargo that reflects key genomic changes, treatment resistance mechanisms, and immune evasion. Although advances are substantial, clinical implementation remains constrained by low analyte concentrations, methodological variability, limited standardization and the high cost of testing, which is rarely reimbursed by insurers. This review summarizes current evidence on circulating biomarkers in GB and highlights research priorities essential for integrating LB into future diagnostic and therapeutic workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansLiquid BiopsyBiomarkers, TumorNeoplastic Cells, CirculatingExtracellular VesiclesCirculating Tumor DNA

Stichwörter der Autor:innen

cell-free nucleic acidscirculating tumor cellsextracellular vesiclesglioblastomaliquid biopsynon-invasive diagnosticstumor heterogeneity

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
  • Department of Research and Development, LEK-AM Pharmaceutical Company Ltd., Inwestycyjna 7 St., 95-050 Konstantynow Lodzki, Poland.

ORCID-Profile: Tomasz Wasiak, Kamil Filiks, Adrianna Rutkowska

Förderung

  • Medical University of Lodz
  • LEK-AM Pharmaceutical Company Ltd.

Zitieren

APA

Wasiak, T., Jaskólska, M., Filiks, K., Bartkowiak, J., & Rutkowska, A. (2026). Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects. Cells. https://doi.org/10.3390/cells15030309

Vancouver

Wasiak T, Jaskólska M, Filiks K, Bartkowiak J, Rutkowska A. Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects. Cells. 2026. doi:10.3390/cells15030309

BibTeX
@article{Wasiak2026,
  author = {Wasiak, Tomasz and Jaskólska, Maria and Filiks, Kamil and Bartkowiak, Jakub and Rutkowska, Adrianna},
  title = {Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15030309}
}
Kostenlos starten →